RxDoctor Payments DataLook up a doctor →

Alejandro Alva, MD

Psychiatry · Costa Mesa, CANPI 1801816764

Payments from drug & device makers

$1,459,085in general payments, 2019–2025

Across 2,539 payments — averaging $574.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$821K
  • Regeneron$130K
  • Janssen Research & Development, LLC$113K
  • Alkermes, Inc.$78K
  • Teva Pharmaceuticals USA, Inc.$66K
  • Neurocrine Biosciences, Inc.$52K
  • plus $200K from 49 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)471$820,879
Regeneron266$129,531
Janssen Research & Development, LLC18$112,675
Alkermes, Inc.139$78,280
Teva Pharmaceuticals USA, Inc.298$65,774
Neurocrine Biosciences, Inc.168$51,541
Novartis2$46,885
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)181$40,167
Otsuka Pharmaceutical Development & Commercialization, Inc.11$31,927
H. Lundbeck A S8$26,306
F. Hoffmann-la Roche AG4$11,808
MDD US Operations, LLC50$10,494
Sunovion Pharmaceuticals Inc.96$7,303
Johnson & Johnson136$3,707
Otsuka America Pharmaceutical, Inc.143$3,311
Biogen19$2,576
Axsome Therapeutics, Inc.29$1,901
Lundbeck LLC103$1,732
Livanova USA, Inc.43$1,568
Vanda Pharmaceuticals Inc.47$1,549
Supernus Pharmaceuticals, Inc.23$885
Neuronetics, Inc.8$859
USWM, LLC23$851
Avanir Pharmaceuticals, Inc.33$798
Takeda Pharmaceuticals U.S.A., Inc.26$798
Indivior Inc.32$742
Bausch Health US, LLC28$461
Noven Therapeutics, LLC20$401
Luye Pharma (USA) Ltd.8$386
Boehringer Ingelheim4$364
Acadia Pharmaceuticals Inc13$336
Idorsia Pharmaceuticals US Inc11$244
Harmony Biosciences LLC7$220
E.r. Squibb & Sons, L.L.C.4$200
Brainsway USA Inc1$197
Braeburn Inc.5$187
Tris Pharma Inc5$162
Merck11$160
Adlon Therapeutics L.p.9$152
Eisai Inc.7$118
Corium, LLC4$95
Ironshore Pharmaceuticals Inc.4$87
Avadel CNS Pharmaceuticals, LLC2$65
Lilly USA, LLC3$64
Boston Scientific1$47
Avion Pharmaceuticals2$44
Sun Pharmaceutical Industries Inc.2$43
Jazz Pharmaceuticals Inc.2$38
Alfasigma USA, Inc.2$34
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$31
Orexo US, Inc.1$23
Pfizer1$22
OWP Pharmaceuticals, Inc.1$21
Assertio Therapeutics, Inc.1$19
Gilead1$19

How this compares

$1,459,085 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California →

Medicare billing

Part B allowed, 2024
$58,436
Medicare patients
122
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Costa Mesa

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →